Published in Dig Dis Sci on April 01, 1997
Probiotics and Multi-Drug Resistant Urinary Tract Infection | NCT03644966
Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut (2003) 5.19
Dysbiosis in inflammatory bowel disease. Gut (2004) 5.01
Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease. J Clin Microbiol (2006) 2.93
Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem (2002) 2.59
Search for localized dysbiosis in Crohn's disease ulcerations by temporal temperature gradient gel electrophoresis of 16S rRNA. J Clin Microbiol (2005) 1.43
Is Crohn's disease due to defective immunity? Gut (2007) 1.21
Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol (2014) 1.19
Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. Dig Dis Sci (2004) 1.18
Health benefits of probiotics: are mixtures more effective than single strains? Eur J Nutr (2011) 1.17
Probiotics and inflammatory bowel disease. J R Soc Med (2003) 1.10
Lifestyle-related disease in Crohn's disease: relapse prevention by a semi-vegetarian diet. World J Gastroenterol (2010) 1.10
Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings. Appl Environ Microbiol (2011) 1.01
Evidence for the involvement of infectious agents in the pathogenesis of Crohn's disease. World J Gastroenterol (2008) 0.95
Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer, diverticulitis and inflammatory bowel disease. World J Gastroenterol (2007) 0.93
Nutritional protective mechanisms against gut inflammation. J Nutr Biochem (2013) 0.92
Immune disorders and its correlation with gut microbiome. Immune Netw (2012) 0.86
Lactobacillus plantarum prevents the upregulation of adhesion molecule expression in an experimental colitis model. Dig Dis Sci (2009) 0.86
The potential interactions between polyunsaturated fatty acids and colonic inflammatory processes. Clin Exp Immunol (2005) 0.84
Probiotics and inflammatory bowel diseases. Postgrad Med J (2006) 0.84
Disease-dependent adhesion of lactic acid bacteria to the human intestinal mucosa. Clin Diagn Lab Immunol (2003) 0.82
Bifidobacterium longum CCM 7952 Promotes Epithelial Barrier Function and Prevents Acute DSS-Induced Colitis in Strictly Strain-Specific Manner. PLoS One (2015) 0.82
Effect of synbiotics on intestinal microflora and digestive enzyme activities in rats. World J Gastroenterol (2005) 0.81
Metabolic profiling of the impact of oligofructose-enriched inulin in Crohn's disease patients: a double-blinded randomized controlled trial. Clin Transl Gastroenterol (2013) 0.80
Carbohydrate Elimination or Adaptation Diet for Symptoms of Intestinal Discomfort in IBD: Rationales for "Gibsons' Conundrum". Int J Inflam (2012) 0.79
Diminished efficacy of colonic adaptation to lactulose occurs in patients with inflammatory bowel disease in remission. Dig Dis Sci (2002) 0.78
Gut Microbial Dysbiosis Due to Helicobacter Drives an Increase in Marginal Zone B Cells in the Absence of IL-10 Signaling in Macrophages. J Immunol (2015) 0.78
Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease. Dig Dis Sci (2011) 0.77
Interrelatedness between dysbiosis in the gut microbiota due to immunodeficiency and disease penetrance of colitis. Immunology (2015) 0.76
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology (1976) 15.65
Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr (1995) 13.30
Regulatory effects of bifidobacteria on the growth of other colonic bacteria. J Appl Bacteriol (1994) 2.09
The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. J Med Microbiol (1991) 1.88
The obligate anaerobic faecal flora of patients with Crohn's disease and their first-degree relatives. Scand J Gastroenterol (1988) 1.83
Studies of intestinal microflora. V. Fecal microbial ecology in ulcerative colitis and regional enteritis: relationship to severity of disease and chemotherapy. Gastroenterology (1968) 1.80
Influence of inflammatory bowel disease on intestinal microflora. Gut (1978) 1.61
Anaerobic gram-negative faecal flora in patients with Crohn's disease and healthy subjects. Antonie Van Leeuwenhoek (1983) 1.56
New medium for selection and presumptive identification of the Bacteroides fragilis group. J Clin Microbiol (1978) 1.55
Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel disease. Gut (1974) 1.47
The faecal flora of patients with Crohn's disease. J Hyg (Lond) (1981) 1.46
Influence of mucin on glycosidase, protease and arylamidase activities of human gut bacteria grown in a 3-stage continuous culture system. J Appl Bacteriol (1989) 1.35
Molecular evidence for two forms of Crohn disease. Proc Natl Acad Sci U S A (1994) 1.11
The microbial flora of the rectal mucosa and faeces of patients with Crohn's disease before and during antimicrobial chemotherapy. J Med Microbiol (1984) 1.07
Faecal mucus degrading glycosidases in ulcerative colitis and Crohn's disease. Gut (1985) 1.02
Lactulose--a potential drug for the treatment of inflammatory bowel disease. Med Hypotheses (1994) 0.89
Total parenteral nutrition and the function of the intestinal microflora in Crohn's disease. Scand J Gastroenterol (1988) 0.88
Increased faecal glycosidases in patients with Crohn's disease. Digestion (1987) 0.85
Variations in concentrations of bacterial metabolites, enzyme activities, moisture, pH and bacterial composition between and within individuals in faeces of seven healthy adults. J Appl Bacteriol (1994) 0.85
Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease. Dig Dis Sci (1995) 0.78
The effect of metronidazole and sulfasalazine on the fecal flora in patients with Crohn's disease. Scand J Gastroenterol (1981) 0.75
[Decrease of fecal beta-galactosidase activity in Crohn disease]. Gastroenterol Clin Biol (1993) 0.75
Decreased faecal exoglycosidase activities identify a subset of patients with active Crohn's disease. Clin Sci (Lond) (1992) 0.75
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis (2010) 6.75
Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 5.44
Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology (1998) 5.02
Dysbiosis in inflammatory bowel disease. Gut (2004) 5.01
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis (2009) 3.22
Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology (1990) 2.58
A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med (1998) 2.54
Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology (1995) 2.47
Genetic analyses of chromosome 12 loci in Crohn's disease. Gut (2000) 2.30
Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun (2001) 2.28
An in-depth study of Crohn's disease in two French families. Gastroenterology (1993) 2.15
European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis (2008) 2.14
Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol (1998) 2.03
Dysbiosis as a prerequisite for IBD. Gut (2004) 1.93
Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol (1996) 1.89
Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J Exp Med (1992) 1.88
Incidence of inflammatory bowel disease in northern France (1988-1990). Gut (1994) 1.81
Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. Gastroenterology (1996) 1.73
Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) Gastroenterology (1993) 1.71
Clinical characteristics of Crohn's disease in 72 families. Gastroenterology (1996) 1.70
The changing pattern of Crohn's disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007). Aliment Pharmacol Ther (2011) 1.69
Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol (2000) 1.69
Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology (1997) 1.69
Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology (1999) 1.68
Treatment of diversion colitis by short-chain fatty acids. Prospective and double-blind study. Dis Colon Rectum (1991) 1.65
Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut (2005) 1.65
Enterocolitis induced by autoimmune targeting of enteric glial cells: a possible mechanism in Crohn's disease? Proc Natl Acad Sci U S A (2001) 1.63
Latent pulmonary involvement in Crohn's disease: biological, functional, bronchoalveolar lavage and scintigraphic studies. Gut (1986) 1.63
Genetically related Escherichia coli strains associated with Crohn's disease. Gut (2001) 1.61
Inflammatory bowel disease in married couples: 10 cases in Nord Pas de Calais region of France and Liège county of Belgium. Gut (1994) 1.57
Perioperative endoscopy of the whole small bowel in Crohn's disease. Gut (1993) 1.54
Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? Lancet (1994) 1.53
Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature. Leukemia (1997) 1.50
Investigation of drug absorption from the gastrointestinal tract of man. I. Metoprolol in the stomach, duodenum and jejunum. Br J Clin Pharmacol (1985) 1.48
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis (2001) 1.44
Evidence of gastritis with several Helicobacter pylori strains. Lancet (1989) 1.43
[Infliximab therapy for Crohn's disease anoperineal lesions]. Gastroenterol Clin Biol (2001) 1.40
Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. Aliment Pharmacol Ther (2008) 1.40
[Adult asthma exacerbations in questions]. Rev Mal Respir (2010) 1.40
[Diagnostic and therapeutic management of patients with chronic inflammatory bowel disease]. Rev Epidemiol Sante Publique (1999) 1.39
Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology (1992) 1.39
[Eosinophils and pathology of the digestive tract]. Gastroenterol Clin Biol (1990) 1.38
Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol (1999) 1.35
Susceptibility of anaerobic bacteria from several French hospitals to three major antibiotics. Antimicrob Agents Chemother (1984) 1.35
Multilocus sequence typing reveals intrafamilial transmission and microevolutions of Candida albicans isolates from the human digestive tract. J Clin Microbiol (2006) 1.34
Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. Gastroenterology (2000) 1.33
Eosinophilic gastroenteritis: ultrastructural evidence for a selective release of eosinophil major basic protein. Clin Exp Immunol (1988) 1.29
Palliative treatment of rectosigmoid carcinoma by laser endoscopic photoablation. Gastroenterology (1987) 1.27
Antibiotics in Crohn's disease. Gut (2001) 1.25
Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients. Am J Gastroenterol (2001) 1.24
Immunoreactivity for interleukin 3 and 5 and granulocyte/macrophage colony-stimulating factor of intestinal mucosa in bronchial asthma. J Exp Med (1995) 1.22
Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999). Gut (2004) 1.20
A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut (2003) 1.19
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther (2010) 1.18
[Study of the F2b fraction of calf thymus histones]. Biochimie (1972) 1.17
Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology (1999) 1.17
Familial expression of anti-Saccharomyces cerevisiae Mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am J Gastroenterol (2001) 1.17
Evidence of linkage of the inflammatory bowel disease susceptibility locus on chromosome 16 (IBD1) to ulcerative colitis. J Med Genet (1998) 1.17
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis (2012) 1.15
Aberrant expression of a human mucin gene (MUC5AC) in rectosigmoid villous adenoma. Gastroenterology (1996) 1.14
Cap polyposis occurring in the postoperative course of pelvic surgery. Gut (1994) 1.12
Impaired bacterial flora in human excluded colon. Gut (1989) 1.12
Wireless capsule endoscopy versus ileocolonoscopy for the diagnosis of postoperative recurrence of Crohn's disease: a prospective study. Gut (2006) 1.12
Qualitative study of fecal alpha 1-proteinase inhibitor in normal subjects and patients with Crohn's disease. Clin Chem (1988) 1.11